Us

Pic:getty/marianvejcik

CPHI NORTH AMERICA 2022

US pharma hubs: The rising stars to watch

By Rachel Arthur

CPhI North America 2022 host city Philadelphia is set to become one of the world’s biggest cell and gene therapy manufacturing hubs. But it’s just one of many centers of innovation that are helping drive the US pharma and biopharma industry.

Pic:getty/oatawa

Astorg to acquire CordenPharma from ICIG

By Rachel Arthur

Astorg will acquire CDMO CordenPharma from ICIG: noting strong organic growth for the CDMO thanks to its position in fast-growing drug modalities such as mRNA vaccines, peptides and high-potency compounds notably for oncology therapeutics.

Pic:getty/moyostudio

Syner-G Biopharma Group acquires Impact

By Rachel Arthur

Syner-G BioPharma Group, a provider of Chemistry, Manufacturing, and Controls (CMC) technical, regulatory, and compliance consulting services to the pharmaceutical and biotechnology industry, has acquired Impact Pharmaceutical Services.

Pic:getty/andrewbrookes

Biogen halves price of Aduhelm in the US

By Rachel Arthur

As of January 1, 2022, Biogen will cut the price of its Alzheimer’s drug Aduhelm (aducanumab-avwa) in half: saying too many patients are not currently being offered the choice of the drug due to financial considerations.

Pic:getty/markogerber

bluebird bio plans ‘new nest’ around hybrid work model

By Rachel Arthur

bluebird bio has signed a long-term lease for a 61,000 square foot facility at Assembly Row, Greater Boston: saying the new headquarters has been designed to reflect modern ways of working and deliver significant cost savings.

Pic:getty/meisuseno

AGC Biologics acquires Colorado CGT facility

By Rachel Arthur

CDMO AGC Biologics has acquired a commercial manufacturing facility in Longmont, Colorado: giving it significant additional capacity and space to expand its global end-to-end cell and gene therapy offering.

Pic:getty/mikemareen

Merck to help manufacture J&J COVID-19 vaccine

By Rachel Arthur

Merck’s US facilities will help manufacture Johnson & Johnson’s COVID-19 vaccine: which a $268.8m injection from the US government helping it adapt existing facilities for COVID-19 vaccines and medicines.

Lucira plans to expand the scope of the EUA next year. Pic: Lucira

FDA authorises first home self-testing kit for COVID-19

By Rachel Arthur

The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the Lucira COVID-19 All-In-One Test Kit: the first COVID-19 diagnostic test for self-testing at home.

(Image: Getty/Ronniechua)

How the US-Mexico trade deal could impact the biologics market

By Ben Hargreaves

BioPharma-Reporter (BPR) discusses with Jennifer Fox (JF), co-chair of Brinks Gilson & Lione’s biopharma practice group, the provisional detail revealed from the US administration’s proposed trade deal with Mexico, and its potential impact on the...